

Writing a tiering exception request letter

A tiering exception request letter can help make medication more affordable for patients covered through **Medicaid or TRICARE** who may not be eligible to participate in savings programs but need assistance covering costs. A tiering exception request letter can help a patient gain access by outlining the reasons why a treatment is necessary to meet the medical needs of the patient.

Tiering exception request letter submission process

A tiering exception is a type of coverage determination used when a medication is on a plan's formulary but is placed in a nonpreferred tier that has a higher co-pay or co-insurance. Plans may make a tier exception when the drug is demonstrated to be medically necessary.

1

The tiering exception request letter may **originate from you, your patient, or your patient's legal representative**.*

2

Typically, your patient's **medical records** and a **letter of medical necessity (LMN)** are submitted with the letter.

3

Both you and your patient **should sign** the letter.

- Plans frequently provide specific tiering exception request templates that must be used when making the request. These forms may be downloaded from each plan's website
- Follow the plan's requirements when requesting SKYRIZI; otherwise, treatment may be delayed†

*Please note for Medicare Part D subscribers: Under the Medicare Part D prescription drug benefit program, a Part D plan enrollee, the enrollee's representative, or the enrollee's doctor or other prescriber can request a coverage determination, including a request for a tiering or formulary exception. A request for a coverage determination can be made orally or in writing. An enrollee, the enrollee's representative, or the enrollee's prescriber may submit a written request for a coverage determination in any format.

†Please note that the Centers for Medicare & Medicaid Services (CMS) has developed "REQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION" model forms that are posted on its website. For more information, visit <https://www.cms.gov/medicare/appeals-and-grievances/medprescriptdrugapplgriev/coveragedeterminationsandexceptions.html>.

Please see Indication and Important Safety Information on page 4.

Please see full Prescribing Information at https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.

Skyrizi™ COMPLETE

Skyrizi™
risankizumab-rzaa
75mg/0.83mL Injection

Sample tiering exception request letter

This is an example of a letter you can use for patients when the prescribed product is on a health plan's formulary but is placed in a nonpreferred tier that has a higher co-pay or co-insurance. This step may require you to submit an LMN with the tiering exception request letter.

[Date]
[Formulary director]
[Name of health plan]
[Mailing address]

Re: [Patient's name]
[Plan identification number]
[Date of birth]
[Case identification]

To whom it may concern:

My name is [HCP's name], and I am a [board-certified medical specialty] [NPI]. I am writing to request a tiering exception for my patient, [patient's name], who is currently a member of [name of health plan].*

The prescription is for [product, dosage and frequency], which is medically appropriate and necessary for this patient who has been diagnosed with [condition], [ICD code(s)].

I am requesting that [product] be made available to my patient as a preferred medication.

In the past, [patient's name] has attempted other treatments for [condition], but those trials have failed due to either inadequate efficacy or lack of tolerability.

| Past Treatment(s)† | Start/Stop Dates | Reason(s) for Discontinuing |
|--------------------|-------------------|---|
| [Drug name] | [MM/YY] - [MM/YY] | [Please list side effects, lack of efficacy, etc] |
| [Drug name] | [MM/YY] - [MM/YY] | [Please list side effects, lack of efficacy, etc] |

The patient's present treatment(s) are as follows:

| Current Treatment(s)† | Start Date | Dosage |
|-----------------------|------------|--------|
| [Drug name] | [MM/YY] | [XX] |
| [Drug name] | [MM/YY] | [XX] |

Currently, [patient's name] has the following unresolved symptoms:

- [Symptom 1]
- [Symptom 2]

Along with this letter, I have enclosed a copy of my patient's medical records and a Letter of Medical Necessity. The letter describes why [product] is medically necessary for my patient's care over the preferred drugs listed in the plan's formulary.

[Explain why lower-tiered formulary drugs would not be as effective as product].

The reason I am requesting a tiering exception is because the cost associated with [product] assigned tier would present a financial burden to [patient's name]. Furthermore, it prevents my patient from utilizing a medication that will help treat the [condition].

To summarize, I consider [product] to be the best option in successfully treating my patient's [condition]. Please contact me, [name], at [telephone number] to answer any pending questions.

Sincerely,

[Physician's name and signature]
[Physician's medical specialty] [Physician's NPI]
[Physician's practice name]
[Phone #] [Fax #]

Encl: [Medical records, photo(s), Letter of Medical Necessity, statement of financial hardship, case number, written response to denial]

NPI, National Provider Identifier

*Include patient's medical records and supporting documentation, including clinical evaluation, scoring forms, and photos of affected areas.

†Identify drug name, strength, dosage form, and therapeutic outcome.

©2019 AbbVie Inc. North Chicago, IL 60064 US-ABBV-190026 April 2019 Printed in U.S.A.

If this appeal has previously been denied, consider including:

This is a tiering exception request letter. I have included a copy of the original denial letter and medical notes in response to the denial.

For previously denied appeals, include the following:

- A copy of the denial letter
- Medical notes, written by the prescribing physician, in response to the denial letter

This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Providers are encouraged to contact third-party payers for specific information about their coverage policies. For more information, please call an Access Specialist at 1.877.COMPLETE (1.877.266.7538).

Digital version available at [CompletePro.com](https://www.completepro.com) and [SkyriziHCP.com](https://www.skyrizihcp.com).

Please see Indication and Important Safety Information on page 4.

Please see full Prescribing Information at https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.

Skyrizi COMPLETE


Skyrizi™
risankizumab-rzaa
75mg/0.83mL Injection

Writing a tiering exception request letter and what to include



Make sure you include all of the information in the letter that is highlighted in red; otherwise, your appeal could be denied



Additional documents

- A letter of medical necessity
- A statement of financial hardship, written by your patient
- Recent photo(s) of the impacted area(s)
- If this letter serves as an appeal, include the case number from the denial letter, a copy of the denial letter, and a written response to the denial

For support in person or over the phone, call your Access Specialist at 1.877.COMPLETE (1.877.266.7538).

Please see Indication and Important Safety Information on page 4.

Please see full Prescribing Information at https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.

Skyrizi™ COMPLETE

Skyrizi™
risankizumab-rzaa
75mg/0.83mL Injection

Indication and Important Safety Information for SKYRIZI

Indication¹

SKYRIZI™ (risankizumab-rzaa) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information¹ Infection

SKYRIZI™ (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Prior to initiating SKYRIZI, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with SKYRIZI.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

Please see full Prescribing Information at https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.

abbvie

©2019 AbbVie Inc. North Chicago, IL 60064 US-RISN-190055 April 2019


Skyrizi™
risankizumab-rzaa
75mg/0.83mL Injection